Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment

British Journal of Cancer

Volumn 106, Issue 2, 2012, Pages 333-343

  Taylor Harding, B ^a   Agadjanian, H ^a   Nassanian, H ^a   Kwon, S ^b   Guo, X ^b   Miller, C ^a   Karlan, B Y ^a,c   Orsulic, S ^a   Walsh, C S ^a,c  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bortezomib; chemosensitivity; indole 3 carbinol (I3C); ovarian cancer; synergy; xenograft tumours

Indexed keywords

3 INDOLEMETHANOL; BORTEZOMIB; CARBOPLATIN; CARCINOGEN; CISPLATIN; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOSKELETON; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; ENDOPLASMIC RETICULUM STRESS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; METABOLISM; MICROARRAY ANALYSIS; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL CYCLE; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HUMANS; INDOLES; MICE; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PYRAZINES; REAL-TIME POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856430416     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.546     Document Type: Article

References (45)

1. Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W; Gynecologic Oncology Group (2009) A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 115: 215-220
2. Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR (2005) Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23: 5943-5949
3. Barton CA, Gloss BS, Qu W, Statham AL, Hacker NF, Sutherland RL, Clark SJ, O'Brien PM (2010) Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival. Br J Cancer 102: 87-96
4. Bast Jr RC, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415-428
5. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925 (Pubitemid 37493640)
6. Boccadoro M, Morgan G, Cavenagh J (2005) Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 5: 18
7. Bruning A, Burger P, Vogel M, Rahmeh M, Friese K, Lenhard M, Burges A (2009) Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Invest New Drugs 27: 543-551
8. Chinni SR, Li Y, Upadhyay S, Koppolu PK, Sarkar FH (2001) Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 20: 2927-2936 (Pubitemid 33027760)
9. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
10. Comoglio PM, Giordano S, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7: 504-516 (Pubitemid 351767118)
11. Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Viganò L, Maur M, Capri G, Maccioni E, Tosi D, Gianni L (2008) Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer 44: 1829-1834
12. Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van Dijk M, Lokhorst HM, Bloem AC, Spaargaren M, Pals ST (2003) The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17: 764-774 (Pubitemid 36519374)
13. Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih JH, Barrett JC, Birrer MJ (2004) Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 23: 8065-8077 (Pubitemid 39531847)
14. Du P, Kibbe WA, Lin SM (2008) Lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547-1548 (Pubitemid 351911712)
15. Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, Chiew YE, Traficante N, Fereday S, Johnson D, Fox S, Sellers W, Urashima M, Salvesen HB, Meyerson M, Bowtell D, AOCS Study Group (2009) Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 15: 1417-1427
16. Falcon S, Gentleman R (2007) Using GOstats to test gene lists for GO term association. Bioinformatics 23: 257-258 (Pubitemid 46189622)
17. Fribley A, Wang CY (2006) Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther 5: 745-748 (Pubitemid 44775127)
18. Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P, Charpin C (2007) Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol 31: 49-58
19. Jin H, Yu Y, Zhang T, Zhou X, Zhou J, Jia L, Wu Y, Zhou BP, Feng Y (2010) Snail is critical for tumor growth and metastasis of ovarian carcinoma. Int J Cancer 126: 2102-2111
20. Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC, Lee HP (2009) Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Res 18: 47-56
21. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116: 1582-1595
22. Kim YU, Ashida H, Mori K, Maeda Y, Hong Y, Kinoshita T (2007) Both mammalian PIG-M and PIG-X are required for growth of GPI14-disrupted yeast. J Biochem 142: 123-129 (Pubitemid 351455370)
23. Landen Jr CN, Birrer MJ, Sood AK (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26: 995-1005 (Pubitemid 351398093)
24. Li Y, Li X, Sarkar FH (2003) Gene expression profiles of I3C-and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. J Nutr 133: 1011-1019 (Pubitemid 36407118)
25. Liu X, Yao W, Newton RC, Scherle PA (2008) Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 17: 997-1011
26. Maeda Y, Watanabe R, Harris CL, Hong Y, Ohishi K, Kinoshita K, Kinoshita T (2001) PIG-M transfers the first mannose to glycosylphosphatidylinositol on the lumenal side of the ER. EMBO J 20: 250-261 (Pubitemid 32099121)
27. Naik R, Nixon S, Lopes A, Godfrey K, Hatem MH, Monaghan JM (2006) A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia. Int J Gynecol Cancer 16: 786-790
28. Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K (2010) Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 116: 2621-2634
29. Nguyen HH, Aronchik I, Brar GA, Nguyen DH, Bjeldanes LF, Firestone GL (2008) The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing. Proc Natl Acad Sci USA 105: 19750-19755
30. Rahman KW, Li Y, Wang Z, Sarkar SH, Sarkar FH (2006) Gene expression profiling revealed survivin as a target of 3,30-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 66: 4952-4960
31. Raj MH, Abd Elmageed ZY, Zhou J, Gaur RL, Nguyen L, Azam GA, Braley P, Rao PN, Fathi IM, Ouhtit A (2008) Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells. Gynecol Oncol 110: 432-438
32. Ramirez PT, Landen Jr CN, Coleman RL, Milam MR, Levenback C, Johnston TA, Gershenson DM (2008) Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum-and taxane-resistant ovarian cancer. Gynecol Oncol 108: 68-71 (Pubitemid 350299423)
33. Reed GA, Peterson KS, Smith HJ, Gray JC, Sullivan DK, Mayo MS, Crowell JA, Hurwitz A (2005) A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev 14: 1953-1960 (Pubitemid 41161206)
34. Rosen CA, Bryson PC (2004) Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J Voice 18: 248-253 (Pubitemid 38757553)
35. Ruschak AM, Slassi M, Kay LE, Schimmer AD (2011) Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 103: 1007-1017
36. Santoro MG (2000) Heat shock factors and the control of the stress response. Biochem Pharmacol 59: 55-63
37. Smyth GK (2005) Limma: linear models for microarray data. In Bioinformatics and Computational Biology Solutions using R and Bioconductor, Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W (eds) pp 397-420. Springer: New York
38. Taylor-Harding B, Orsulic S, Karlan BY, Li AJ (2010) Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Gynecol Oncol 119: 549-556
39. Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Al-Kuraya KS (2008) Bortezomib (velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res 68: 3379-3388
40. Uddin S, Ahmed M, Hussain AR, Jehan Z, Al-Dayel F, Munkarah A, Bavi P, Al-Kuraya KS (2009) Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer. Lab Invest 89: 1115-1127
41. Weng JR, Tsai CH, Kulp SK, Chen CS (2008) Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett 262: 153-163
42. Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK, Koh J, Chan SL, Chan AT, Lai PB, Ching AK, Tong JH, Ng HK, Johnson PJ, To KF (2009) TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer 124: 644-652
43. Wright JJ (2010) Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 16: 4094-4104
44. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR (2001) Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 98: 247-252 (Pubitemid 32095895)
45. Zimmermann J, Erdmann D, Lalande I, Grossenbacher R, Noorani M, Furst P (2000) Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1. Oncogene 19: 2913-2920 (Pubitemid 30389081)